Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Abstract: An example method of treating a medical issue includes applying a composition to a skin area corresponding to a location afflicted with the medical issue. The composition includes a blend of Cannabidiol (CBD) oil and Cannabinol (CBN) oil fortified with curcumin from turmeric, Boswellic acid, and polycyclic terpenes from Boswellia serrata. The medical issue includes at least one of osteoarthritis, joint pain associated with natural causes or injury, reduced joint function and flexibility after injury or other causes, and photo-aging. A composition including a blend of pure CBD oil and CBN oil fortified with curcumin from turmeric and Boswellic acid along with polycyclic terpenes from Boswellia serrata is also disclosed.